NESS ZIONA, Israel – Feb. 3, 2026 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will present new safety and efficacy data from the GA Depot...
NESS ZIONA, Israel – Jan. 6, 2026 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 44th Annual J.P. Morgan Healthcare...
Management to Participate in 8th Annual Evercore Annual Healthcare Conference NESS ZIONA, Israel – Dec. 1, 2025 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot...
NESS ZIONA, Israel – Sep. 17, 2025 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on developing innovative long-acting depot injectable treatments, today provided an update on the clinical development program...
NESS ZIONA, Israel – Dec. 2, 2024 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 7th Annual Evercore HealthCONx...
Meeting to feature latest clinical findings on GA Depot and showcase commitment to improving care for people living with multiple sclerosis (MS) NESS ZIONA, Israel – Oct. 10, 2023 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development... 